Edition:
United States

Merck & Co Inc (MRK)

MRK on New York Consolidated

60.25USD
23 Apr 2018
Change (% chg)

$1.42 (+2.41%)
Prev Close
$58.83
Open
$60.05
Day's High
$60.62
Day's Low
$59.43
Volume
19,815,744
Avg. Vol
12,773,305
52-wk High
$66.41
52-wk Low
$52.83

Chart for

About

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes... (more)

Overall

Beta: 0.79
Market Cap(Mil.): $158,570.70
Shares Outstanding(Mil.): 2,695.41
Dividend: 0.48
Yield (%): 3.26

Financials

  MRK Industry Sector
P/E (TTM): 32.33 31.01 33.60
EPS (TTM): 1.82 -- --
ROI: 6.83 13.60 13.19
ROE: 13.42 15.26 15.00

BRIEF-EMA Validates Type II Variation For Merck's Keytruda In Combination With Pemetrexed And Platinum Chemotherapy

* EUROPEAN MEDICINES AGENCY VALIDATES TYPE II VARIATION FOR MERCK’S KEYTRUDA® (PEMBROLIZUMAB) IN COMBINATION WITH PEMETREXED (ALIMTA®) AND PLATINUM CHEMOTHERAPY AS FIRST-LINE THERAPY IN METASTATIC NONSQUAMOUS NSCLC, BASED ON PHASE 3 KEYNOTE-189 TRIAL Source text for Eikon: Further company coverage:

Apr 23 2018

US STOCKS-Wall St little changed as bond yields inch higher

* Indexes: Dow and Nasdaq flat, S&P up 0.13 pct (Updates to early afternoon)

Apr 23 2018

U.S. biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

Apr 20 2018

UPDATE 2-U.S. biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON, April 20 Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

Apr 20 2018

CORRECTED-UPDATE 1-U.S. biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON, April 20 Dicerna Pharmaceuticals Inc on Friday said that it will pay $15 million plus stock to Alnylam Pharmaceuticals Inc to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

Apr 20 2018

BRIEF-Merck Announces First Phase 3 Studies For Pcv-15 (V114), Its Investigational Pneumococcal Disease Vaccine

* MERCK ANNOUNCES FIRST PHASE THREE STUDIES FOR PCV-15 (V114) ITS INVESTIGATIONAL PNEUMOCOCCAL DISEASE VACCINE

Apr 17 2018

BRIEF-Labcyte Reaches Agreement With Merck To Supply Acoustic-Mass Spectrometry Equipment

* LABCYTE REACHES AGREEMENT WITH MERCK TO SUPPLY ACOUSTIC-MASS SPECTROMETRY EQUIPMENT

Apr 17 2018

Survival data boosts Merck's Keytruda lead in lung cancer

NEW YORK/CHICAGO Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival in newly-diagnosed patients with advanced non-small cell lung cancer in a closely-watched study, cementing its lead position over Bristol-Myers Squibb Co and others in the most lucrative oncology market.

Apr 16 2018

UPDATE 2-Survival data boosts Merck's Keytruda lead in lung cancer

NEW YORK/CHICAGO, April 16 Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival in newly-diagnosed patients with advanced non-small cell lung cancer in a closely-watched study, cementing its lead position over Bristol-Myers Squibb Co and others in the most lucrative oncology market.

Apr 16 2018

Merck, Bristol-Myers immunotherapies impress in key lung cancer trials

April 16 Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival versus chemotherapy alone in newly-diagnosed patients with advanced non-small cell lung cancer in a highly-anticipated study that appears to cement the company's lead in the most lucrative oncology market.

Apr 16 2018

Competitors

Earnings vs. Estimates